惯性聚合 高效追踪和阅读你感兴趣的博客、新闻、科技资讯
阅读原文 在惯性聚合中打开

推荐订阅源

Last Week in AI
Last Week in AI
H
Help Net Security
博客园 - 叶小钗
V
Visual Studio Blog
阮一峰的网络日志
阮一峰的网络日志
博客园 - 三生石上(FineUI控件)
钛媒体:引领未来商业与生活新知
钛媒体:引领未来商业与生活新知
Microsoft Azure Blog
Microsoft Azure Blog
G
Google Developers Blog
腾讯CDC
MongoDB | Blog
MongoDB | Blog
宝玉的分享
宝玉的分享
P
Proofpoint News Feed
GbyAI
GbyAI
Microsoft Security Blog
Microsoft Security Blog
A
About on SuperTechFans
博客园 - 司徒正美
人人都是产品经理
人人都是产品经理
T
The Blog of Author Tim Ferriss
Martin Fowler
Martin Fowler
月光博客
月光博客
博客园 - 聂微东
酷 壳 – CoolShell
酷 壳 – CoolShell
Vercel News
Vercel News

All Articles on Seeking Alpha

All Eyes On Cencora, A Healthcare Supplier That Could See Lots More Upside Simply Good Foods Doesn't Look Like A Growth Stock Anymore Applied Digital: Post-Earnings Clarity Confirms An Accelerated Path To $1 Billion NOI Target IBIT: Why I Stepped To The Side (Technical Analysis) (Rating Downgrade) XES: Oil Service Stocks Turn Pricey; Why It's Time To Take Profits (Rating Downgrade) The Only Dividend Strategy I'd Trust In A 3.5% Fed Funds World Opera: AI-Driven Advertising Prospects - Upside Potential And Rich Dividend Yields RenaissanceRe: Preferred Stock Hasn't Been This Appealing In Years Q1 Earnings Kick Off With Major Banks' Results: Bank of America, Netflix In Focus Sezzle: Consolidation Completed, Re-Rating Ahead Bitmine Immersion Q2 Preview: Ethereum Thesis Facing Important Report Card I Am Sharing 2 Of My Retirement High-Yield Gems The Software Narrative Is Leaking Badly Again Thanks To Anthropic Mythos The Muni Market Looks Appealing In Q2 AVIV: Should Keep Rising If The Ceasefire Holds Foundayo Explained: Lilly's New Weight Loss Pill And The Amazon Effect Sabesp: A New Privatization As An Opportunity! EchoStar: Potential Bull Trap At Play - Take Gains Off The Table Teladoc Health: Improving Fundamentals Support A Turnaround Story March CPI Inflation: 5 Reasons To Stay Calm Two 12%+ Yielding BDC Bargains (One Is My Top Deep-Value Pick) TechnipFMC: We Prefer Saipem With More Room To Improve Tesla: From Bye-Bye To Buy-Buy (Rating Upgrade) DMB: Vulnerable To High Interest Rates Western Midstream: A 9% Yield That Still Grows In A Downturn IQQQ: Tax-Efficient Income From The Nasdaq But Does Not Protect Against Declines Qualys Share Price Pulled Down By Potential Cybersecurity Disruptor S&P 500: A Dead Money Era May Be Here. How To Thrive In It Vistance Networks Looks Better Than Before With Powerful Earnings Growth Commerce Bancshares: Valuation, Not Quality, Is The Problem
RenovoRx, Inc. (RNXT) Presents at IAccess Alpha Virtual B...
SA Transcripts · 2026-06-24 · via All Articles on Seeking Alpha

RenovoRx, Inc. (RNXT) IAccess Alpha Virtual Best Ideas Summer Investment Conference 2026 June 23, 2026 12:30 PM EDT

Company Participants

Shaun Bagai - CEO, Secretary & Director
Mark Voll - CFO & Principal Accounting Officer

Presentation

Operator

Good day, and welcome to the iAccess Alpha Virtual Best Ideas Summer Investment Conference 2026. Our next presenting company is RenovoRx Inc. [Operator Instructions]

I'd now like to turn the floor over to today's host, Shaun Bagai, Chief Executive Officer of RenovoRx Inc. Please go ahead.

Shaun Bagai
CEO, Secretary & Director

Thank you for the introduction, and thank you for the opportunity here, and thanks, everyone, for joining in. Shaun Bagai here, CEO of RenovoRx, and I'm also joined by my CFO, Chief Financial Officer, Mark Voll, who will chime in at the appropriate times.

So I wanted to give you a little overview on our company, our background, how the technology works and the opportunities that lay ahead of us. When we think about cancer and therapies in cancer, it's quite often a balance of trying to attack a tumor and not destroying the patient in the meantime. And what we've seen with therapeutic after therapeutic that the biggest blockbusters are, let's try to extend life by a few weeks to months. And hopefully, we don't have the worst possible ever quality life for patients. And it's that kind of balance and give and take on both sides.

At RenovoRx, we're trying to attack this very differently on is there a way that we can actually attack the tumor, keep the tumor at bay, extend life and also not destroy the patient in the process and maintain a relatively high quality of life and full function. And it looks like we're starting to achieve that.

So as a background, I'll go to